The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.
Noopur S. Raje
Consultant or Advisory Role - Amgen
Evangelos Terpos
Consultant or Advisory Role - Amgen; Janssen-Cilag; MorphoSys
Honoraria - Celgene; Novartis
Research Funding - Amgen; Janssen-Cilag
Brian G. Durie
No relevant relationships to disclose
Ramon Garcia-Sanz
Honoraria - Amgen
Research Funding - Novartis
Kazuyuki Shimizu
Consultant or Advisory Role - Daiichi Sankyo
Honoraria - Daiichi Sankyo
Research Funding - Daiichi Sankyo
Expert Testimony - Amgen (U)
Wolfgang Willenbacher
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Li Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ada H. Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Rajul K. Jain
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Antonio Palumbo
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx